Drug therapy in the heart transplant recipient. Part IV: Drug-drug interactions

Circulation

Volumn 111, Issue 2, 2005, Pages 230-239

  Page II, Robert L ^a   Miller, Geraldine G ^b   Lindenfeld, JoAnn ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Drugs; Immunology; Rejection; Transplantation

Indexed keywords

AMLODIPINE; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; CYTOCHROME P450; DILTIAZEM; EVEROLIMUS; EZETIMIBE; FELODIPINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; MEVINOLIN; NICARDIPINE; PRAVASTATIN; RAPAMYCIN; ROSUVASTATIN; SIMVASTATIN; TACROLIMUS; TICLOPIDINE; UNINDEXED DRUG; VERAPAMIL;

AGRANULOCYTOSIS; ANEMIA; DRUG DELIVERY SYSTEM; DRUG MONITORING; HEART TRANSPLANTATION; HUMAN; LEUKOPENIA; MYOPATHY; NEUTROPENIA; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR;

ANTI-INFECTIVE AGENTS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; CARDIOVASCULAR AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN; PLATELET AGGREGATION INHIBITORS;

EID: 12344325443     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000151805.86933.35     Document Type: Review

References (113)

1. Lindenfeld J, Miller GG, Shakar SF, Zolty R, Lowes BD, Wolfel E, Mestroni L, Page RL II, Kobashigawa J. Drug therapy in the heart transplant recipient, part I: cardiac rejection and immunosuppressive drugs. Circulation. 2004;110:3734-3740.
2. Hansten PD. Understanding drug-drug interactions. Sci Med. 1998;5:16-25.
3. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38:41-57.
4. Shapiro LE, Shear NH. Drug interactions: proteins, pumps, and P-450s. J Am Acad Dermatol. 2002;47:467-484.
5. Dipiro JT, Spruill WJ, Blouin RA, Pruemer JM. Concepts in Clinical Pharmacokinetics. 3rd ed. Bethesda, Md: American Society of Health-System Pharmacists; 2002.
6. Tatro DS, ed. Drug Interaction Facts. Chicago, Ill: St Louis Facts and Comparisons, Wolters Kluwer Health, Inc; February 2004; xv-xviii.
7. Shaw LM, Korecka M, DeNofrio D, Brayman KL. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem. 2001;34:17-22.
8. Meiser BM, Pfeiffer M, Schmidt D, Reichenspurner H, Ueberfuhr P, Paulus D, von Scheidt W, Kreuzer E, Seidel D, Reichart B. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant. 1999;18:143-149.
9. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Eight-year results of cyclosporine-treated patients with cardiac transplants. J Thorac Cardiovasc Surg. 1990;99:500-509.
10. Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporin: an update. Clin Pharmacokinet. 1996;30:141-179.
11. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404-430.
12. Grino JM, Sabate I, Castelao AM, Alsina. J. Influence of diltiazem on cyclosporin clearance. Lancet. 1986;1:1387.
13. Chrysostomou A, Walker RG, Russ GR, d'Apice AJ, Kincaid-Smith P, Mathew TH. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation. 1993;55:300-304.
14. Campistol JM, Oppenheimer F, Vilardell J, Ricart MJ, Alcaraz A, Ponz E, Andreu J. Interaction between ciclosporin and diltiazem in renal transplant patients. Nephron. 1991;57:241-242.
15. Wagner K, Neumayer HH. Prevention of delayed graft function in cadaver kidney transplants by diltiazem. Lancet. 1985;2:1355-1356. Letter.
16. Tortorice KL, Heim-Duthoy KL, Awni WM, Rao KV, Kasiske BL. The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients. Ther Drug Monit. 1990;12:321-328.
17. Lindholm A, Henricsson S. Verapamil inhibits cyclosporin metabolism. Lancet. 1987;1:1262-263. Letter.
18. Katari SR, Magnone M, Shapiro R, Jordan M, Scantlebury V, Vivas C, Gritsch A, McCauley J, Starzl T, Demetris AJ, Randhawa PS. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. Clin Transplant. 1997;11:237-242.
19. Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother. 1999;33:680-682.
20. Cantarovich M, Hiesse C, Lockiec F, Charpentier B, Fries D. Confirmation of the interaction between cyclosporine and the calcium channel blocker nicardipine in renal transplant patients. Clin Nephrol. 1987;28:190-193.
21. Pesavento TE, Jones PA, Julian BA, Curtis JJ. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. J Am Soc Nephrol. 1996;7:831-835.
22. Kessler M, Netter P, Renoult E, Jonon B, Mur JM, Trechot P, Dousset B. Influence of nicardipine on renal function and plasma cyclosporin in renal transplant patients. Eur J Clin Pharmacol. 1989;36:637-638.
23. van der Schaaf MR, Hene RJ, Floor M, Blankestijn PJ, Koomans HA. Hypertension after renal transplantation: calcium channel or converting enzyme blockade? Hypertension. 1995;25:77-81.
24. McGregor DO, Bailey RR, Robson RA. Amlodipine has a minor effect on cyclosporine metabolism. Clin Nephrol. 1997;48:336. Letter.
25. Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. Eur J Clin Pharmacol. 1996;50:203-208.
26. Yeleswaram K. Comment on "Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine." Eur J Clin Pharmacol. 1997;52:159, 161.
27. Butani L, Berg G, Makker SP. Effect of felodipine on tacrolimus pharmacokinetics in a renal transplant recipient. Transplantation. 2002;73:159-160. Letter.
28. Seifeldin RA, Marcos-Alvarez A, Gordon FD, Lewis WD, Jenkins RL. Nifedipine interaction with tacrolimus in liver transplant recipients. Ann Pharmacother. 1997;31:571-575.
29. Endresen L, Bergan S, Holdaas H, Pran T, Sinding-Larsen B, Berg KJ. Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients. Ther Drug Monit. 1991;13:490-495. Letter.
30. Martinez F, Pirson Y, Wallemacq P, van Ypersele de Strihou C. No clinically significant interaction between ciclosporin and isradipine. Nephron. 1991;59:658-659.
31. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JP, Stein EA. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163:553-564.
32. Cheng-Lai A. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Heart Dis. 2003;5:72-78.
33. Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J. 2004;147:956-965.
34. Crestor [package insert]. Wilmington, Del: AstraZeneca Pharmaceuticals; August 2003.
35. Gullestad L, Nordal KP, Berg KJ, Cheng H, Schwartz MS, Simonsen S. Interaction between lovastatin and cyclosporine A after heart and kidney transplantation. Transplant Proc. 1999;31:2163-2165.
36. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron. 1993;65:410-413.
37. Ichimaru N, Takahara S, Kokado Y, Wang JD, Hatori M, Kameoka H, Inoue T, Okuyama A. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis. 2001;158:417-23.
38. Campana C, Iacona I, Regazzi MB, Gavazzi A, Perani G, Raddato V, Montemartini C, Vigano M. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. Ann Pharmacother. 1995;29:235-239.
39. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation. 1996;62:1559-1564.
40. Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant. 2001;1:382-386.
41. Park JW, Siekmeier R, Lattke P, Merz M, Mix C, Schuler S, Jaross W. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. J Cardiovasc Pharmacol Ther. 2001;6:351-361.
42. Kliem V, Wanner C, Eisenhauer T, Olbricht CJ, Doll R, Boddaert M, O'Grady P, Krekler M, Mangold B, Christians U. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. Transplant Proc. 1996;28:3126-3128.
43. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O'Grady P, Krekler M, Mangold B, Christians U. Accumulation of lovastatin, but not pravastafin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 1997;62:311-321.
44. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002;41:813-851.
45. Lindenfeld J, Page RL II, Miller GG, Shakar SF, Zolty R, Lowes BD, Wolfel E, Mestroni L. Drug therapy in the heart transplant recipient, part III: common medical problems and drug-drug interactions. Circulation. 2005;111:113-117.
46. Zetia [package insert]. North Wales, Penn: Merck/Schering-Plough Pharmaceuticals; October 2003.
47. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998;34:155-162.
48. Pisanti N, Stanziale P, Imperatore P, D'Alessandro R, De Marino V, Capone D. Lack of effect of gemfibrozil on cyclosporine blood concentrations in kidney-transplanted patients. Am J Nephrol. 1998;18:199-203.
49. Fehrman-Ekholm I, Jogestrand T, Angelin B. Decreased cyclosporine levels during gemfibrozil treatment of hyperlipidemia after kidney transplantation. Nephron. 1996;72:483.
50. Boissonnat P, Salen P, Guidollet J, Ferrera R, Dureau G, Ninet J, Renaud S, de Lorgeril M. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation. 1994;58:245-247.
51. Birmele B, Lebranchu Y, Bagros P, Nivet H, Furet Y, Pengloan J. Interaction of cyclosporin and ticlopidine. Nephrol Dial Transplant. 1991;6:150-151.
52. Feriozzi S, Massimetti C, Ancarani E. Treatment with ticlopidine is associated with reduction of cyclosporin A blood levels. Nephron. 2002;92:249-250.
53. Boissonnat P, de Lorgeril M, Perroux V, Salen P, Batt AM, Barthelemy JC, Brouard R, Serres E, Delaye J. A drug interaction study between ticlopidine and cyclosporin in heart transplant recipients. Eur J Clin Pharamcol. 1997;53:39-45.
54. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003;107:32-37.
55. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol. 1991;32:624-626.
56. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother. 2002;46:3091-3093.
57. Lopez-Gil JA. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharmacother. 1993;27:427-430.
58. Ullmann AJ. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin. 2003;19:263-2-71.
59. Cancidas [package insert]. North Wales, Penn; Merck Pharmaceuticals; January 2003.
60. Helms-Smith KM, Curtis SL, Hatton RC. Apparent interaction between nefazodone and cyclosporine. Ann Intern Med. 1996;125:424. Letter.
61. Wright DH, Lake KD, Bruhn PS, Emery RW Jr. Nefazodone and cyclosporine drug-drug interaction. J Heart Lung Transplant. 1999;18:913-915.
62. Horton RC, Bonser RS. Interaction between cyclosporin and fluoxetine. BMJ. 1995;311:422.
63. Garton T. Nefazodone and CYP450 3A4 interactions with cyclosporine and tacrolimus. Transplantation. 2002;74:745.
64. Olyaei AJ, deMattos AM, Norman DJ, Bennett WM. Interaction between tacrolimus and nefazodone in a stable renal transplant recipient. Pharmacotherapy. 1998;18:1356-1359.
65. Liston HL, Markowitz JS, Hunt N, DeVane CL, Boulton DW, Ashcraft E. Lack of citalopram effect on the pharmacokinetics of cyclosporine. Psychosomatics. 2001;42:370-372. Letter.
66. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000;68:598-604.
67. Ernst E. St John's Wort supplements endanger the success of organ transplantation. Arch Surg. 2002;137:316-319.
68. Nicolau DP, Uber WE, Crumbley AJ 3rd, Strange C. Amiodarone-cyclosporine interaction in a heart transplant patient. J Heart Lung Transplant. 1992;11:564-568.
69. Chitwood KK, Abdul-Haqq AJ, Heim-Duthoy KL. Cyclosporine-amiodarone interaction. Ann Pharmacother. 1993;27:569-571.
70. Preuner JG, Lehle K, Keyser A, Merk J, Rupprecht L, Goebels R. Development of severe adverse effects after discontinuing amiodarone therapy in human heart transplant recipients. Transplant Proc. 1998;30:3943-3944.
71. Freeman DJ, Laupacis A, Keown PA, Stiller CR, Carruthers SG. Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol. 1984;18:887-893.
72. Karasu Z, Gurakar A, Carlson J, Pennington S, Kerwin B, Wright H, Nour B, Sebastian A. Acute tacrolimus overdose and treatment with phenytoin in liver transplant recipients. J Okla State Med Assoc. 2001;94:121-123.
73. Rowland M, Gupta SK. Cyclosporin-phenytoin interaction: re-evaluation using metabolite data. Br J Clin Pharmacol. 1987;24:329-334.
74. Schmidt H, Naumann R, Jaschonek K, Einsele H, Dopfer R, Ehninger G. Drug interaction between cyclosporin and phenytoin in allogeneic bone marrow transplantation. Bone Marrow Transplant. 1989;4:212-213.
75. Thompson PA, Mosley CA. Tacrolimus-phenytoin interaction. Ann Pharmacother. 1996;30:544.
76. Schweitzer EJ, Canafax DM, Gillingham KJ, Najarian JS, Matas AJ. Phenytoin administration in renal allograft recipients on cyclosporine immunosuppression. Clin Transplant. 1993;7:9-13.
77. Soto Alvarez J, Sacristan Del Castillo JA, Alsar Ortiz MJ. Effect of carbamazepine on cyclosporin blood level. Nephron. 1991;58:235-236.
78. Rosche J, Froscher W, Abendroth D, Liebel J. Possible oxcarbazepine interaction with cyclosporine serum levels: a single case study. Clin Neuropharmacol. 2001;24:113-116.
79. Prograf [package insert]. Deerfield, Ill: Fujisawa Healthcare, Inc; July 2001.
80. Simkin PA, Gardner GC. Colchicine use in cyclosporine treated transplant recipients: how little is too much? J Rheumatol. 2000;27:1334-1337.
81. Sands M, Brown RB. Interactions of cyclosporine with antimicrobial agents. Rev Infect Dis. 1989;11:691-697.
82. Lake KD. Management of drug interactions with cyclosporine. Pharmacotherapy. 1991;11:110S-118S.
83. Paterson DL, Singh N. Interactions between tacrolimus and antimicrobial agents. Clin Infect Dis. 1997;25:1430-1440.
84. Levy GA, Grant D, Paradis K, Campestrini J, Smith T, Kovarik JM. Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation. 2001;71:160-163.
85. MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther. 2000;22(suppl B):B101-B121.
86. Bottiger Y, Sawe J, Brattstrom C, Tollemar J, Burke JT, Hass G, Zimmerman JJ. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. Clin Pharmacol Ther. 2001;69:32-40.
87. Kovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharamcol Ther. 2001;70:247-254.
88. Floren LC, Christians U, Zimmerman JJ, Neefe L, Schorer R, Rushworth D, Harper D, Renz J, Benet LZ. Sirolimus oral bioavailability increases ten-fold with concomitant ketoconazole. Clin Pharmacol Ther. 1999;65:159. Abstract.
89. Cervelli MJ. Fluconazole-sirolimus drug interaction. Transplantation. 2002;74:1477-1478.
90. Rapamune [package insert]. Philadelphia, Penn: Wyeth-Ayerst Pharmaceuticals Inc; April 2003.
91. Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther. 1998;63:48-53.
92. Kovarik JM, Kalbag J, Figueiredo J, Rouilly M, Frazier OL, Rordorf C. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol. 2002;42:95-99.
93. Brattstrom C, Wilczek H, Tyden G, Bottiger Y, Sawe J, Groth CG. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation. 1998;65:1272-1274.
94. Kovarik JM, Kaplan B, Tedesco Silva H, Kahan BD, Dantal J, Vitko S, Boger R, Rordorf C. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation. 2002;73:920-925.
95. Kovarik JM, Hartmann S, Hubert M, Berthier S, Schneider W, Rosenkranz B, Rordorf C. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol. 2002;42:222-228.
96. Wiseman AC, Kam I, Christians U, Jani A, Bak T, Wachs M, Chan L. Fixed-dose sirolimus with reduced dose calcineurin inhibitor: the University of Colorado experience. Transplant Proc. 2003;35:122S-124S.
97. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
98. Cellcept [package insert]. Nutley, NJ: Roche Laboratories; March 2003.
99. Bullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol. 1996;41:513-516.
100. Morii M, Ueno K, Ogawa A, Kato R, Yoshimura H, Wada K, Hashimoto H, Takada M, Tanaka K, Nakatani T, Shibakawa M. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther. 2000;68:613-616.
101. Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol. 1997;5:225-232.
102. Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy. Transplant Proc. 1997;29:334-336.
103. Hubner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit. 1999;21:536-539.
104. van Gelder T, Smak Gregoor PJ, Weimar W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit. 2000;22:639.
105. Gregoor PJ, de Sevaux RG, Hene RJ, Hesse CJ, Hilbrands LB, Vos P, van Gelder T, Hoitsma AJ, Weimar W. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation. 1999;68:1603-1606.
106. Smak Gregoor PJ, van Gelder T, Hesse CJ, van der Mast BJ, van Besouw NM, Weimar W. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant. 1999;14:706-708.
107. Lennard L. Clinical implications of thiopurine methyltransferase: optimization of drug dosage and potential drug interactions. Ther Drug Monit. 1998;20:527-531.
108. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother. 1996;30:951-954.
109. Rivier G, Khamashta MA, Hughes GR. Warfarin and azathioprine: a drug interaction does exist. Am J Med. 1993;95:342. Letter.
110. Rotenberg M, Levy Y, Shoenfeld Y, Almog S, Ezra D. Effect of azathioprine on the anticoagulant activity of warfarin. Ann Pharmacother. 2000;34:120-122. Letter.
111. Walker J, Mendelson H, McClure A, Smith MD. Warfarin and azathioprine: clinically significant drug interaction. J Rheumatol. 2002;29:398-399. Letter.
112. Elijovisch F, Krakoff LR. Captopril associated granulocytopenia in hypertension after renal transplantation. Lancet. 1980;1:927-928. Letter.
113. Gossmann J, Kachel HG, Schoeppe W, Scheuermann EH. Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors. Transplantation. 1993;56:585-589.